Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vor Biopharma Inc. (VOR)
USD18.30
-0.20 (-1.06%)
US NASDAQ Healthcare Biotechnology
Address
100 Cambridgepark Drive 2140
Cambridge, MA, US
Cambridge, MA, US
CEO
Jean-Paul Kress
Website
vorbio.com
IPO
2021-02-05
CIK 1817229 ISIN US9290332074
Description
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
News Sentiment (7d)
Based on only 2 articles — low confidence
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD18.30
-0.20 (-1.06%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1M
Beta
1.73
Float Shares
4.89M
Free Float %
71.3%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.40% | -0.44% | -0.38% | +24.49% | +63.18% | +21.64% | +397.19% | -82.00% | -95.96% | -97.88% | -97.88% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (13 ratings, all time)
Buy
Price Targets & DCF
Current price
18.30
Low
31.00
+69.4%
Consensus
38.50
+110.3%
Median
38.50
+110.3%
High
46.00
+151.3%
DCF (Unlevered)
39.40
+115.2%
DCF (Levered)
39.86
+117.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
89% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 7 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
31.00
+69.4%
|
| Last Quarter | 1 |
31.00
+69.4%
|
| Last Year | 6 |
42.33
+131.3%
|
| All Time | 7 |
37.14
+102.9%
|
Quality scores
Altman Z-Score
-9.88
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
2 / 5
Medium
DCF Score
5 / 5
High
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-107.4% Q1'26: +1.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+187.4% Q1'26: +589.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.01× Q1'26: -0.02× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 7 Rev. Ana. 6 EPS Ana. |
Dec 2027 9 Rev. Ana. 6 EPS Ana. |
Dec 2028 8 Rev. Ana. 7 EPS Ana. |
Dec 2029 7 Rev. Ana. 2 EPS Ana. |
Dec 2030 7 Rev. Ana. 5 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 2.00M (-100.0%)
|
4.17M
4.17M – 4.17M
+108.3% YoY
|
10.00M
10.00M – 10.00M
+140.0% YoY
|
28.90M
28.87M – 28.93M
+189.0% YoY
|
193.86M
193.86M – 193.86M
+570.8% YoY
|
476.06M
476.06M – 476.06M
+145.6% YoY
|
| EBITDA |
-117.66M
|
-368.76M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-121.19M
|
-371.64M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-116.91M
est: -96.65M (-21.0%)
|
-695.98M
est: -688.50M (-1.1%)
|
-36.61M
-42.76M – -30.47M
+94.7% YoY
|
-38.39M
-41.91M – -34.87M
-4.9% YoY
|
-47.47M
-72.75M – -22.19M
-23.6% YoY
|
-23.76M
-23.76M – -23.76M
+50.0% YoY
|
-1.99M
-1.99M – -1.99M
+91.6% YoY
|
| SGA |
27.88M
|
50.11M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-34.00
est: -28.74 (-18.3%)
|
-70.50
est: -69.75 (-1.1%)
|
-3.58
-4.33 – -3.09
+94.9% YoY
|
-3.96
-4.25 – -3.53
-10.6% YoY
|
-4.31
-7.37 – -2.25
-8.9% YoY
|
-2.41
-2.41 – -2.41
+44.2% YoY
|
-0.20
-0.20 – -0.20
+91.6% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 2/5 | 5/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
19
Total invested
39.91M
Insider transactions (90d)
3
Beneficial owners (>5%)
11
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Peter Kolchinsky | 11.12M | 30.00% | — | 11.12M | — | 10.00 | HC, IN | United States | 2021-02-19 | ↗ |
| 2 | RA Capital Management, L.P. | 11.12M | 30.00% | — | 11.12M | — | 10.00 | IA, PN | Delaware | 2021-02-19 | ↗ |
| 3 | Rajeev Shah | 11.12M | 30.00% | — | 11.12M | — | 10.00 | HC, IN | United States | 2021-02-19 | ↗ |
| 4 | RA Capital Healthcare Fund, L.P. | 8.30M | 22.40% | — | 8.30M | — | 10.00 | PN | Delaware | 2021-02-19 | ↗ |
| 5 | Andrew J. Schwab | 6.69M | 18.00% | — | 6.69M | — | 11.00 | IN | — | 2021-02-19 | ↗ |
| 6 | Dr. Kush Parmar | 6.69M | 18.00% | — | 6.69M | — | 11.00 | IN | — | 2021-02-19 | ↗ |
| 7 | 5AM Partners VI, LLC | 4.83M | 13.00% | — | 4.83M | — | 11.00 | OO | — | 2021-02-19 | ↗ |
| 8 | 5AM Ventures VI, L.P. | 4.83M | 13.00% | — | 4.83M | — | 11.00 | PN | — | 2021-02-19 | ↗ |
| 9 | FMR LLC | 3.94M | 10.60% | 764.2K | — | 3.94M | — | HC | Delaware | 2021-03-10 | ↗ |
| 10 | 5AM Opportunities I (GP), LLC | 1.86M | 5.00% | — | 1.86M | — | 11.00 | OO | — | 2021-02-19 | ↗ |
| 11 | 5AM Opportunities I, L.P. | 1.86M | 5.00% | — | 1.86M | — | 11.00 | PN | — | 2021-02-19 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
19
-42 vs prev Q
New positions
12
Closed positions
47
Increased
16
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | — | 1,000.0K +1,000.0K (+100.0%) | 13.08B +13.1B (+100.0%) | 14.97% +14.966 pp | 7.67% +7.672 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 5.40M +3.4M (+172.7%) | 70.70M -25.9M (-26.8%) | 80.89% +51.224 pp | 0.72% -0.466 pp | USD26.15 -50.0% | 2 qtrs — |
| 3 | FCPM III SERVICES B.V. | 3.62M +3.2M (+852.8%) | 47.31M +28.8M (+155.8%) | 54.14% +48.456 pp | 6.20% +2.506 pp | USD16.82 -22.2% | 2 qtrs — |
| 4 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 2.54M +2.5M (+100.0%) | 33.27M +33.3M (+100.0%) | 38.07% +38.073 pp | 0.89% +0.894 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 5 | FMR LLC | 2.53M +2.3M (+968.1%) | 33.04M +21.5M (+186.8%) | 37.81% +34.267 pp | 0.00% +0.001 pp | USD16.42 -20.3% | 2 qtrs — |
| 6 | VR ADVISER, LLC | 1.94M +1.4M (+288.8%) | 25.42M +1.1M (+4.4%) | 29.09% +21.608 pp | 1.26% -0.115 pp | USD22.25 -41.2% | 2 qtrs — |
| 7 | PARADIGM BIOCAPITAL ADVISORS LP | 1.75M +1.8M (+100.0%) | 22.89M +22.9M (+100.0%) | 26.19% +26.191 pp | 0.58% +0.584 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 8 | GREAT POINT PARTNERS LLC | 1.37M +1.4M (+100.0%) | 17.92M +17.9M (+100.0%) | 20.51% +20.505 pp | 5.81% +5.811 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 999.3K -4.2M (-80.9%) | 13.07M -241.7M (-94.9%) | 14.96% -63.309 pp | 0.00% -0.028 pp | USD48.72 -73.2% | 2 qtrs — |
| 10 | VANGUARD GROUP INC | 770.3K +665.1K (+632.2%) | 10.07M +5.0M (+96.6%) | 11.53% +9.953 pp | 0.00% +0.000 pp | USD17.95 -27.1% | 2 qtrs — |
| 11 | CALIGAN PARTNERS LP | 925.1K +925.1K (+100.0%) | 9.96M +10.0M (+100.0%) | 13.84% +13.845 pp | 0.82% +0.820 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 12 | BLACKROCK, INC. | 465.6K +431.1K (+1,248.5%) | 6.09M +4.4M (+262.0%) | 6.97% +6.452 pp | 0.00% +0.000 pp | USD15.72 -16.8% | 2 qtrs — |
| 13 | CITADEL ADVISORS LLC | 433.9K +428.2K (+7,530.9%) | 5.68M +5.4M (+1,948.7%) | 6.49% +6.409 pp | 0.00% +0.001 pp | USD13.55 -3.5% | 2 qtrs — |
| 14 | SPHERA FUNDS MANAGEMENT LTD. | 410.4K +410.4K (+100.0%) | 5.37M +5.4M (+100.0%) | 6.14% +6.142 pp | 1.04% +1.038 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 15 | LAURION CAPITAL MANAGEMENT LP | 317.2K +317.2K (+100.0%) | 4.15M +4.1M (+100.0%) | 4.75% +4.748 pp | 0.15% +0.155 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 16 | UBS GROUP AG | 292.1K +216.2K (+284.8%) | 3.82M +122.6K (+3.3%) | 4.37% +3.236 pp | 0.00% +0.000 pp | USD22.34 -41.5% | 2 qtrs — |
| 17 | FINDELL CAPITAL MANAGEMENT LLC | 231.0K +231.0K (+100.0%) | 3.02M +3.0M (+100.0%) | 3.46% +3.457 pp | 0.87% +0.869 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 18 | MILLENNIUM MANAGEMENT LLC | 224.5K +199.8K (+806.7%) | 2.94M +1.7M (+143.4%) | 3.36% +2.990 pp | 0.00% +0.001 pp | USD17.01 -23.1% | 2 qtrs — |
| 19 | GEODE CAPITAL MANAGEMENT, LLC | 185.8K +158.4K (+578.3%) | 2.43M +1.1M (+82.2%) | 2.78% +2.371 pp | 0.00% +0.000 pp | USD18.33 -28.6% | 2 qtrs — |
| 20 | TUDOR INVESTMENT CORP ET AL | 167.7K +167.7K (+100.0%) | 2.19M +2.2M (+100.0%) | 2.51% +2.509 pp | 0.00% +0.004 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 21 | AMERIPRISE FINANCIAL INC | 163.1K +163.1K (+100.0%) | 2.13M +2.1M (+100.0%) | 2.44% +2.440 pp | 0.00% +0.001 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 22 | GOLDMAN SACHS GROUP INC | 145.6K +129.9K (+822.6%) | 1.90M +1.1M (+147.7%) | 2.18% +1.943 pp | 0.00% +0.000 pp | USD16.94 -22.8% | 2 qtrs — |
| 23 | LOGOS GLOBAL MANAGEMENT LP | 100.0K +100.0K (+100.0%) | 1.31M +1.3M (+100.0%) | 1.50% +1.497 pp | 0.08% +0.079 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 24 | JANE STREET GROUP, LLC | 91.8K +75.1K (+448.0%) | 1.20M +384.7K (+47.1%) | 1.37% +1.123 pp | 0.00% +0.000 pp | USD19.58 -33.2% | 2 qtrs — |
| 25 | STATE STREET CORP | 91.1K +82.0K (+905.7%) | 1.19M +749.9K (+170.0%) | 1.36% +1.227 pp | 0.00% +0.000 pp | USD16.62 -21.3% | 2 qtrs — |
| 26 | JOHNSON & JOHNSON | 53.7K +— (+0.0%) | 702.8K -1.9M (-73.2%) | 0.80% +0.000 pp | 0.13% -0.390 pp | USD48.72 -73.2% | 2 qtrs — |
| 27 | NORTHERN TRUST CORP | 38.9K +38.9K (+100.0%) | 509.4K +509.4K (+100.0%) | 0.58% +0.583 pp | 0.00% +0.000 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 28 | MORGAN STANLEY | 28.5K +24.0K (+538.8%) | 372.3K +155.2K (+71.5%) | 0.43% +0.359 pp | 0.00% +0.000 pp | USD18.66 -29.9% | 2 qtrs — |
| 29 | ENGINEERS GATE MANAGER LP | 28.2K +28.2K (+100.0%) | 368.9K +368.9K (+100.0%) | 0.42% +0.422 pp | 0.00% +0.004 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 30 | QUADRATURE CAPITAL LTD | 26.8K +26.8K (+100.0%) | 350.4K +350.4K (+100.0%) | 0.40% +0.401 pp | 0.00% +0.004 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 31 | SARISSA CAPITAL MANAGEMENT LP | 25.4K +— (+0.0%) | 332.2K -905.2K (-73.2%) | 0.38% +0.000 pp | 0.15% -0.537 pp | USD48.72 -73.2% | 2 qtrs — |
| 32 | BOLLARD GROUP LLC | 24.0K +21.2K (+763.8%) | 314.0K +179.0K (+132.6%) | 0.36% +0.317 pp | 0.01% +0.005 pp | USD17.21 -24.0% | 2 qtrs — |
| 33 | HUDSON BAY CAPITAL MANAGEMENT LP | 21.3K +— (+0.0%) | 278.0K -757.4K (-73.2%) | 0.32% +0.000 pp | 0.00% -0.003 pp | USD48.72 -73.2% | 2 qtrs — |
| 34 | OMERS ADMINISTRATION CORP | 20.7K +20.7K (+100.0%) | 270.8K +270.8K (+100.0%) | 0.31% +0.310 pp | 0.00% +0.002 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 35 | SQUAREPOINT OPS LLC | 18.5K +13.7K (+290.3%) | 241.4K +11.0K (+4.8%) | 0.28% +0.206 pp | 0.00% +0.000 pp | USD22.21 -41.1% | 2 qtrs — |
| 36 | XTX TOPCO LTD | 17.5K +17.5K (+100.0%) | 229.4K +229.4K (+100.0%) | 0.26% +0.263 pp | 0.01% +0.006 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 37 | PERSISTENT ASSET PARTNERS LTD | 10.8K +10.8K (+100.0%) | 141.2K +141.2K (+100.0%) | 0.16% +0.162 pp | 0.06% +0.063 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 38 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 10.2K +10.2K (+100.0%) | 133.5K +133.5K (+100.0%) | 0.15% +0.153 pp | 0.00% +0.002 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 39 | CHUNG WU INVESTMENT GROUP, LLC | 8.3K +8.3K (+100.0%) | 108.6K +108.6K (+100.0%) | 0.12% +0.124 pp | 0.09% +0.089 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 40 | CITIGROUP INC | 6.3K +6.3K (+100.0%) | 82.9K +82.9K (+100.0%) | 0.09% +0.095 pp | 0.00% +0.000 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 41 | BELVEDERE TRADING LLC | 57.4K -57.7K (-50.1%) | 37.3K -243.5K (-86.7%) | 0.86% -0.864 pp | 0.00% 0.000 pp | USD48.72 -73.2% | 2 qtrs — |
| 42 | CHINA UNIVERSAL ASSET MANAGEMENT CO., LTD. | 2.7K +2.7K (+100.0%) | 35.9K +35.9K (+100.0%) | 0.04% +0.041 pp | 0.00% +0.003 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 43 | JPMORGAN CHASE & CO | 2.3K +2.2K (+2,864.1%) | 30.2K +26.4K (+695.8%) | 0.03% +0.033 pp | 0.00% +0.000 pp | USD14.28 -8.4% | 2 qtrs — |
| 44 | TOWER RESEARCH CAPITAL LLC (TRC) | 1.7K +1.7K (+43,125.0%) | 22.6K +22.4K (+11,497.4%) | 0.03% +0.026 pp | 0.00% +0.001 pp | USD13.16 -0.6% | 2 qtrs — |
| 45 | MIRAE ASSET GLOBAL INVESTMENTS CO., LTD. | 819.00 +819.0 (+100.0%) | 10.7K +10.7K (+100.0%) | 0.01% +0.012 pp | 0.00% +0.000 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 46 | BANK OF AMERICA CORP /DE/ | 396.00 -4.4K (-91.7%) | 5.2K -226.4K (-97.8%) | 0.01% -0.065 pp | 0.00% +0.000 pp | USD48.72 -73.2% | 2 qtrs — |
| 47 | GF FUND MANAGEMENT CO. LTD. | 330.00 +330.0 (+100.0%) | 4.3K +4.3K (+100.0%) | 0.00% +0.005 pp | 0.00% +0.000 pp | USD13.08 +0.0% | 1 qtrs NEW |
| 48 | BNP PARIBAS ARBITRAGE, SNC | 291.00 -5.8K (-95.2%) | 3.8K -292.2K (-98.7%) | 0.00% -0.087 pp | 0.00% 0.000 pp | USD48.72 -73.2% | 2 qtrs — |
| 49 | MAI CAPITAL MANAGEMENT | 40.00 +— (+0.0%) | 524.00 -1.4K (-73.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD48.70 -73.1% | 2 qtrs — |
| 50 | ALLWORTH FINANCIAL LP | 3.00 +— (+0.0%) | 40.00 -107.0 (-72.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD48.67 -73.1% | 2 qtrs — |
| 51 | SBI SECURITIES CO., LTD. | 3.00 +— (+0.0%) | 39.00 -107.0 (-73.3%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD48.67 -73.1% | 2 qtrs — |
| 52 | WELLS FARGO & COMPANY/MN | 1.00 +— (+0.0%) | 13.00 -36.0 (-73.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD48.00 -72.8% | 2 qtrs — |
| 53 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | — -6.3K (-100.0%) | — -304.5K (-100.0%) | 0.00% -0.094 pp | 0.00% -0.007 pp | USD— | 2 qtrs SOLD |
| 54 | BARCLAYS PLC | — -11.0K (-100.0%) | — -7.7K (-100.0%) | 0.00% -0.165 pp | 0.00% +0.000 pp | USD— | 11 qtrs SOLD |
| 55 | VIRTU FINANCIAL LLC | — -8.1K (-100.0%) | — -395.0K (-100.0%) | 0.00% -0.121 pp | 0.00% -0.022 pp | USD— | 2 qtrs SOLD |
| 56 | ARIOSE CAPITAL MANAGEMENT LTD | — -110.2K (-100.0%) | — -5.4M (-100.0%) | 0.00% -1.649 pp | 0.00% -1.800 pp | USD— | 2 qtrs SOLD |
| 57 | WOODLINE PARTNERS LP | — -27.4K (-100.0%) | — -1.3M (-100.0%) | 0.00% -0.410 pp | 0.00% -0.006 pp | USD— | 2 qtrs SOLD |
| 58 | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | — -4.6K (-100.0%) | — -223.9K (-100.0%) | 0.00% -0.069 pp | 0.00% -0.034 pp | USD— | 2 qtrs SOLD |
| 59 | SHAY CAPITAL LLC | — -53.8K (-100.0%) | — -2.6M (-100.0%) | 0.00% -0.805 pp | 0.00% -0.227 pp | USD— | 2 qtrs SOLD |
| 60 | RENAISSANCE TECHNOLOGIES LLC | — -14.6K (-100.0%) | — -711.3K (-100.0%) | 0.00% -0.219 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 61 | CAITONG INTERNATIONAL ASSET MANAGEMENT CO., LTD | — -110.0 (-100.0%) | — -5.4K (-100.0%) | 0.00% -0.002 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 62 | TANG CAPITAL MANAGEMENT LLC | — -50.0K (-100.0%) | — -2.4M (-100.0%) | 0.00% -0.748 pp | 0.00% -0.094 pp | USD— | 2 qtrs SOLD |
| 63 | POLYMER CAPITAL MANAGEMENT (HK) LTD | — -21.2K (-100.0%) | — -1.0M (-100.0%) | 0.00% -0.318 pp | 0.00% -0.143 pp | USD— | 2 qtrs SOLD |
| 64 | SCIENTECH RESEARCH LLC | — -6.1K (-100.0%) | — -297.0K (-100.0%) | 0.00% -0.091 pp | 0.00% -0.104 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 63 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Virtus Biotech Clinical Trials ETF BBC | 0.82% | 472.2K | 0.65% |
| 2 | ALPS Medical Breakthroughs ETF SBIO | 0.53% | 1.13M | 0.50% |
| 3 | Global X - S&P Biotech ETF CURE.AX | 0.31% | 112.2K | 0.45% |
| 4 | State Street SPDR S&P Biotech ETF XBI | 0.31% | 33.71M | 0.35% |
| 5 | Invesco Russell 2000 Dynamic Multifactor ETF OMFS | 0.19% | 540.7K | 0.39% |
| 6 | iShares Micro-Cap ETF IWC | 0.18% | 2.62M | 0.60% |
| 7 | American Century Small Cap Growth Insights ETF ACSG | 0.12% | 30.9K | 0.49% |
| 8 | Invesco NASDAQ Biotech UCITS ETF SBIO.L | 0.07% | 329.9K | 0.40% |
| 9 | Invesco Nasdaq Biotechnology ETF IBBQ | 0.07% | 53.3K | 0.19% |
| 10 | iShares Nasdaq US Biotechnology UCITS ETF BTEE.L | 0.07% | 52.2K | 0.35% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
15
Shares acquired
—
Shares disposed
3.00M
Cash buys
—
Cash sales
15.00
Net activity
-3,002,903
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-22 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 165,150 | 15.77 | 2.60M | 2,402,095 | I | ↗ |
| 2026-04-20 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 171,963 | 15.77 | 2.71M | 2,567,245 | I | ↗ |
| 2026-04-17 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 458,411 | 16.28 | 7.46M | 2,739,208 | I | ↗ |
| 2026-04-15 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 53,644 | 16.01 | 858.8K | 3,197,619 | I | ↗ |
| 2026-04-14 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 153,735 | 15.97 | 2.46M | 3,251,263 | I | ↗ |
| 2026-04-13 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 530,610 | 16.15 | 8.57M | 3,404,998 | I | ↗ |
| 2026-04-10 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 828 | 15.75 | 13.0K | 3,935,608 | I | ↗ |
| 2026-04-09 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 135,201 | 16.59 | 2.24M | 3,936,436 | I | ↗ |
| 2026-04-08 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 353,242 | 16.32 | 5.76M | 4,202,499 | I | ↗ |
| 2026-04-06 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 537,754 | 16.51 | 8.88M | 4,607,244 | I | ↗ |
| 2026-04-02 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 258,475 | 18.23 | 4.71M | 5,146,523 | I | ↗ |
| 2026-04-01 | Sokolove Jeremy Brett | Officer | — | — | Common Stock | 0 | 0.00 | — | 27,900 | D | ↗ |
| 2026-03-30 | TCG Crossover GP II, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 2,836,539 | I | ↗ |
| 2025-12-18 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 3,000 | 12.80 | 38.4K | 3,000 | I | ↗ |
| 2025-12-18 | Levin Andrew David | Director | A-Award | A | Stock Option (Right to Buy) | 3,000 | 12.80 | 38.4K | 3,000 | D | ↗ |
| 2025-12-18 | Joustra Wouter | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-05 | Zuraw Qing Che | Officer | A-Award | A | Employee Stock Option (right to buy) | 218,652 | 8.18 | 1.79M | 218,652 | D | ↗ |
| 2025-12-05 | Mahatme Sandesh | Officer | A-Award | A | Employee Stock Option (right to buy) | 1,388,274 | 17.80 | 24.71M | 1,388,274 | D | ↗ |
| 2025-12-05 | Kress Jean-Paul | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 4,164,831 | 8.18 | 34.07M | 4,164,831 | D | ↗ |
| 2025-10-30 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 24,579 | 25.12 | 617.4K | 779,652 | I | ↗ |
| 2025-10-29 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 251,518 | 25.22 | 6.34M | 804,231 | I | ↗ |
| 2025-10-28 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 87,828 | 27.10 | 2.38M | 1,092,232 | I | ↗ |
| 2025-10-27 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 90,941 | 28.12 | 2.56M | 1,180,060 | I | ↗ |
| 2025-10-24 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 53,345 | 28.01 | 1.49M | 1,271,001 | I | ↗ |
| 2025-10-23 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 76,880 | 28.01 | 2.15M | 1,324,346 | I | ↗ |
| 2025-10-21 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 200 | 30.08 | 6.0K | 1,166,909 | D | ↗ |
| 2025-10-21 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 25,027 | 28.11 | 703.5K | 1,401,226 | I | ↗ |
| 2025-10-20 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 11,616 | 30.05 | 349.1K | 1,167,109 | D | ↗ |
| 2025-10-20 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 13,817 | 29.63 | 409.4K | 1,287 | I | ↗ |
| 2025-10-17 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 24,689 | 30.22 | 746.1K | 1,179,753 | D | ↗ |
| 2025-10-17 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 174,594 | 29.12 | 5.08M | 1,546,621 | I | ↗ |
| 2025-10-16 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 2,021 | 30.45 | 61.5K | 1,204,442 | D | ↗ |
| 2025-10-16 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 21,804 | 29.32 | 639.3K | 61,032 | I | ↗ |
| 2025-10-15 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 14,851 | 31.05 | 461.1K | 1,263,267 | D | ↗ |
| 2025-10-15 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | S-Sale | D | Common Stock | 42,699 | 30.55 | 1.30M | 1,848,336 | I | ↗ |
| 2025-10-14 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 33,668 | 30.32 | 1.02M | 1,278,118 | D | ↗ |
| 2025-10-13 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 19,672 | 32.36 | 636.6K | 1,314,120 | D | ↗ |
| 2025-10-10 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 40,983 | 30.97 | 1.27M | 1,333,792 | D | ↗ |
| 2025-10-09 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 33,842 | 31.92 | 1.08M | 1,389,817 | D | ↗ |
| 2025-10-08 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 60,926 | 33.75 | 2.06M | 1,437,995 | D | ↗ |
| 2025-10-07 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 27,624 | 33.84 | 934.7K | 1,498,921 | D | ↗ |
| 2025-10-06 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 17,760 | 36.00 | 639.4K | 1,579,548 | D | ↗ |
| 2025-10-03 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 4,701 | 38.14 | 179.3K | 1,597,308 | D | ↗ |
| 2025-10-02 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 13,001 | 40.13 | 521.7K | 1,610,509 | D | ↗ |
| 2025-10-01 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 1,400 | 39.19 | 54.9K | 1,637,660 | D | ↗ |
| 2025-09-18 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Pre-Funded Warrant (Right to Buy) | 10,000,000 | 0.00 | 20.0K | 10,000,000 | I | ↗ |
| 2025-09-16 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 447,278 | 1.54 | 688.9K | 32,781,209 | D | ↗ |
| 2025-09-15 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 400,000 | 1.64 | 656.3K | 33,228,487 | D | ↗ |
| 2025-09-12 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 300,000 | 1.75 | 526.2K | 33,628,487 | D | ↗ |
| 2025-09-11 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 284,805 | 1.83 | 521.4K | 33,928,487 | D | ↗ |
| 2025-09-10 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 350,000 | 1.82 | 635.3K | 34,213,292 | D | ↗ |
| 2025-09-09 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 449,226 | 2.00 | 898.6K | 34,563,292 | D | ↗ |
| 2025-09-08 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 464,421 | 1.99 | 924.1K | 35,012,518 | D | ↗ |
| 2025-09-08 | Reed Sarah Burgess | Director | A-Award | A | Stock Option (Right to Buy) | 60,000 | 1.98 | 118.8K | 60,000 | D | ↗ |
| 2025-09-08 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 60,000 | 1.98 | 118.8K | 60,000 | I | ↗ |
| 2025-09-05 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 400,000 | 1.97 | 787.3K | 35,476,939 | D | ↗ |
| 2025-09-04 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 453,016 | 1.93 | 873.6K | 35,876,939 | D | ↗ |
| 2025-09-03 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 554,612 | 2.00 | 1.11M | 36,329,955 | D | ↗ |
| 2025-08-28 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 806,351 | 2.01 | 1.62M | 36,884,567 | D | ↗ |
| 2025-08-27 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 611,647 | 2.01 | 1.23M | 37,690,918 | D | ↗ |
| 2025-08-27 | Reed Sarah Burgess | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-08-26 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 284,190 | 2.08 | 591.3K | 38,302,565 | D | ↗ |
| 2025-08-25 | Reprogrammed Interchange LLC | 10% Owner | S-Sale | D | Common Stock | 387,346 | 2.12 | 819.7K | 38,586,755 | D | ↗ |
| 2025-07-17 | Zuraw Qing Che | Officer | A-Award | A | Employee Stock Option (right to buy) | 4,373,040 | 2.38 | 10.41M | 4,373,040 | D | ↗ |
| 2025-07-16 | Detheux Michel | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-16 | Cumbo Alexander | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-07-09 | Mahatme Sandesh | Officer | A-Award | A | Common Stock | 13,882,750 | 0.00 | — | 13,882,750 | D | ↗ |
| 2025-06-26 | Kress Jean-Paul | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 83,296,638 | 0.89 | 74.13M | 83,296,638 | D | ↗ |
| 2025-06-25 | Kress Jean-Paul | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-05-22 | Resnick Joshua | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.19 | 5.6K | 30,000 | D | ↗ |
| 2025-05-22 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.19 | 5.6K | 30,000 | I | ↗ |
| 2025-05-22 | Patterson Matthew R | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.19 | 5.6K | 30,000 | D | ↗ |
| 2025-05-22 | Namouni Fouad | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.19 | 5.6K | 30,000 | D | ↗ |
| 2025-05-22 | Lundberg Sven Ante | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.19 | 5.6K | 30,000 | D | ↗ |
| 2025-05-22 | Lubner David Charles | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.19 | 5.6K | 30,000 | D | ↗ |
| 2025-05-22 | Kalir Erez | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.19 | 5.6K | 30,000 | D | ↗ |
| 2025-05-22 | Beckman Daniella | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 0.19 | 5.6K | 30,000 | D | ↗ |
| 2025-05-06 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 876 | 0.56 | 490.56 | 217,416 | D | ↗ |
| 2025-05-06 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,361 | 0.56 | 1.3K | 911,318 | D | ↗ |
| 2025-05-01 | Choi Han Wook | Officer | F-InKind | D | Common Stock | 2,061 | 0.66 | 1.4K | 51,280 | D | ↗ |
| 2025-05-01 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 985 | 0.66 | 650.10 | 219,254 | D | ↗ |
| 2025-05-01 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,751 | 0.66 | 1.8K | 916,201 | D | ↗ |
| 2025-02-13 | Attar Eyal C. | Officer | S-Sale | D | Common Stock | 2,227 | 1.42 | 3.2K | 126,625 | D | ↗ |
| 2025-02-10 | Attar Eyal C. | Officer | S-Sale | D | Common Stock | 2,554 | 1.37 | 3.5K | 128,852 | D | ↗ |
| 2025-02-06 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 1,033 | 1.50 | 1.5K | 220,239 | D | ↗ |
| 2025-02-06 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 1,180 | 1.50 | 1.8K | 131,406 | D | ↗ |
| 2025-02-06 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,787 | 1.50 | 4.2K | 918,952 | D | ↗ |
| 2025-02-03 | Choi Han Wook | Officer | A-Award | A | Common Stock | 52,500 | 0.00 | — | 52,500 | D | ↗ |
| 2025-02-03 | Chakraborty Tirtha | Officer | A-Award | A | Employee Stock Option (right to buy) | 95,500 | 1.34 | 128.0K | 95,500 | D | ↗ |
| 2025-02-03 | Attar Eyal C. | Officer | A-Award | A | Employee Stock Option (right to buy) | 109,000 | 1.34 | 146.1K | 109,000 | D | ↗ |
| 2025-02-03 | ANG ROBERT | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 470,000 | 1.34 | 629.8K | 470,000 | D | ↗ |
| 2025-01-06 | Kalir Erez | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.74 | 104.4K | 60,000 | D | ↗ |
| 2024-12-30 | Reprogrammed Interchange LLC | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-30 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Warrant (Right to Buy) | 21,121,449 | 0.84 | 17.70M | 21,121,449 | I | ↗ |
| 2024-12-27 | Attar Eyal C. | Officer | S-Sale | D | Common Stock | 10,334 | 1.25 | 12.9K | 81,439 | D | ↗ |
| 2024-11-06 | Quinlan Amy | Officer | F-InKind | D | Common Stock | 206 | 0.86 | 177.16 | 50,312 | D | ↗ |
| 2024-11-06 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 875 | 0.86 | 752.50 | 169,935 | D | ↗ |
| 2024-11-06 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 999 | 0.86 | 859.14 | 91,773 | D | ↗ |
| 2024-11-06 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,361 | 0.86 | 2.0K | 787,487 | D | ↗ |
| 2024-11-01 | Quinlan Amy | Officer | F-InKind | D | Common Stock | 343 | 0.80 | 274.40 | 50,518 | D | ↗ |
| 2024-11-01 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 986 | 0.80 | 788.80 | 170,810 | D | ↗ |
| 2024-11-01 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 1,146 | 0.80 | 916.80 | 92,772 | D | ↗ |
| 2024-11-01 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,751 | 0.80 | 2.2K | 789,848 | D | ↗ |
| 2024-09-30 | Choi Han Wook | Officer | A-Award | A | Employee Stock Option (right to buy) | 400,000 | 0.70 | 280.0K | 400,000 | D | ↗ |
| 2024-09-03 | Quinlan Amy | Officer | F-InKind | D | Common Stock | 4,402 | 0.83 | 3.7K | 50,861 | — | ↗ |
| 2024-09-03 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 5,576 | 0.83 | 4.6K | 171,796 | — | ↗ |
| 2024-09-03 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 12,657 | 0.83 | 10.5K | 792,599 | — | ↗ |
| 2024-08-06 | Quinlan Amy | Officer | F-InKind | D | Common Stock | 206 | 0.87 | 179.22 | 55,263 | — | ↗ |
| 2024-08-06 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 876 | 0.87 | 762.12 | 177,372 | — | ↗ |
| 2024-08-06 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 999 | 0.87 | 869.13 | 93,918 | — | ↗ |
| 2024-08-06 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,361 | 0.87 | 2.1K | 805,256 | — | ↗ |
| 2024-08-01 | Quinlan Amy | Officer | F-InKind | D | Common Stock | 343 | 0.94 | 322.42 | 55,469 | — | ↗ |
| 2024-08-01 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 985 | 0.94 | 925.90 | 178,248 | — | ↗ |
| 2024-08-01 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 1,146 | 0.94 | 1.1K | 94,917 | — | ↗ |
| 2024-08-01 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,751 | 0.94 | 2.6K | 807,617 | — | ↗ |
| 2024-06-21 | Quinlan Amy | Officer | — | D | Employee Stock Option (right to buy) | 117,127 | 1.90 | 223.0K | 0 | — | ↗ |
| 2024-06-03 | Attar Eyal C. | Officer | S-Sale | D | Common Stock | 14,645 | 1.39 | 20.4K | 96,063 | — | ↗ |
| 2024-05-23 | Resnick Joshua | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | — | ↗ |
| 2024-05-23 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | — | ↗ |
| 2024-05-23 | Patterson Matthew R | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | — | ↗ |
| 2024-05-23 | Namouni Fouad | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | — | ↗ |
| 2024-05-23 | Lundberg Sven Ante | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | — | ↗ |
| 2024-05-23 | Lubner David Charles | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | — | ↗ |
| 2024-05-23 | Beckman Daniella | Director | A-Award | A | Stock Option (Right to Buy) | 30,000 | 1.61 | 48.3K | 30,000 | — | ↗ |
| 2024-05-06 | Jorgensen Nathan D. | Officer | F-InKind | D | Common Stock | 834 | 1.75 | 1.5K | 189,403 | — | ↗ |
| 2024-05-06 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 875 | 1.75 | 1.5K | 179,233 | — | ↗ |
| 2024-05-06 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 999 | 1.75 | 1.7K | 110,708 | — | ↗ |
| 2024-05-06 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,361 | 1.75 | 4.1K | 810,368 | — | ↗ |
| 2024-05-01 | Jorgensen Nathan D. | Officer | F-InKind | D | Common Stock | 917 | 1.77 | 1.6K | 190,237 | — | ↗ |
| 2024-05-01 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 985 | 1.77 | 1.7K | 180,108 | — | ↗ |
| 2024-05-01 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 1,146 | 1.77 | 2.0K | 111,707 | — | ↗ |
| 2024-05-01 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,751 | 1.77 | 4.9K | 812,729 | — | ↗ |
| 2024-04-30 | Namouni Fouad | Director | A-Award | A | Stock Option (right to buy) | 60,000 | 1.72 | 103.2K | 60,000 | — | ↗ |
| 2024-03-01 | Jorgensen Nathan D. | Officer | F-InKind | D | Common Stock | 6,310 | 2.27 | 14.3K | 191,154 | — | ↗ |
| 2024-03-01 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 5,576 | 2.27 | 12.7K | 181,093 | — | ↗ |
| 2024-03-01 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 12,657 | 2.27 | 28.7K | 815,480 | — | ↗ |
| 2024-02-06 | Jorgensen Nathan D. | Officer | F-InKind | D | Common Stock | 985 | 2.32 | 2.3K | 197,464 | — | ↗ |
| 2024-02-06 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 1,033 | 2.32 | 2.4K | 186,669 | — | ↗ |
| 2024-02-06 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 1,180 | 2.32 | 2.7K | 112,853 | — | ↗ |
| 2024-02-06 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,788 | 2.32 | 6.5K | 828,137 | — | ↗ |
| 2024-01-29 | Jorgensen Nathan D. | Officer | A-Award | A | Employee Stock Option (right to buy) | 100,000 | 2.41 | 241.0K | 100,000 | — | ↗ |
| 2024-01-29 | Chakraborty Tirtha | Officer | A-Award | A | Employee Stock Option (right to buy) | 107,500 | 2.41 | 259.1K | 107,500 | — | ↗ |
| 2024-01-29 | Attar Eyal C. | Officer | A-Award | A | Common Stock | 62,500 | 0.00 | — | 114,033 | — | ↗ |
| 2024-01-29 | ANG ROBERT | Director / Officer | A-Award | A | Common Stock | 150,000 | 0.00 | — | 830,925 | — | ↗ |
| 2023-11-06 | Jorgensen Nathan D. | Officer | F-InKind | D | Common Stock | 834 | 1.82 | 1.5K | 145,647 | — | ↗ |
| 2023-11-06 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 876 | 1.82 | 1.6K | 133,952 | — | ↗ |
| 2023-11-06 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 999 | 1.82 | 1.8K | 51,533 | — | ↗ |
| 2023-11-06 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,361 | 1.82 | 4.3K | 680,925 | — | ↗ |
| 2023-09-01 | Jorgensen Nathan D. | Officer | F-InKind | D | Common Stock | 6,310 | 2.67 | 16.8K | 146,481 | — | ↗ |
| 2023-09-01 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 5,576 | 2.67 | 14.9K | 134,828 | — | ↗ |
| 2023-09-01 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 12,657 | 2.67 | 33.8K | 683,286 | — | ↗ |
| 2023-08-07 | Jorgensen Nathan D. | Officer | F-InKind | D | Common Stock | 834 | 2.67 | 2.2K | 152,791 | — | ↗ |
| 2023-08-07 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 875 | 2.67 | 2.3K | 140,404 | — | ↗ |
| 2023-08-07 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 999 | 2.67 | 2.7K | 52,532 | — | ↗ |
| 2023-08-07 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,361 | 2.67 | 6.3K | 695,943 | — | ↗ |
| 2023-05-26 | Resnick Joshua | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 4.79 | 143.7K | 30,000 | — | ↗ |
| 2023-05-26 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 30,000 | 4.79 | 143.7K | 30,000 | — | ↗ |
| 2023-05-26 | Patterson Matthew R | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 4.79 | 143.7K | 30,000 | — | ↗ |
| 2023-05-26 | Lundberg Sven Ante | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 4.79 | 143.7K | 30,000 | — | ↗ |
| 2023-05-26 | Lubner David Charles | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 4.79 | 143.7K | 30,000 | — | ↗ |
| 2023-05-26 | Beckman Daniella | Director | A-Award | A | Stock Option (right to buy) | 30,000 | 4.79 | 143.7K | 30,000 | — | ↗ |
| 2023-05-08 | Jorgensen Nathan D. | Officer | F-InKind | D | Common Stock | 834 | 4.14 | 3.5K | 153,625 | — | ↗ |
| 2023-05-08 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 875 | 4.14 | 3.6K | 141,279 | — | ↗ |
| 2023-05-08 | Attar Eyal C. | Officer | F-InKind | D | Common Stock | 969 | 4.14 | 4.0K | 53,531 | — | ↗ |
| 2023-05-08 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 2,361 | 4.14 | 9.8K | 698,304 | — | ↗ |
| 2023-03-01 | Jorgensen Nathan D. | Officer | F-InKind | D | Common Stock | 6,310 | 5.51 | 34.8K | 154,459 | — | ↗ |
| 2023-03-01 | Chakraborty Tirtha | Officer | F-InKind | D | Common Stock | 5,576 | 5.51 | 30.7K | 142,154 | — | ↗ |
| 2023-03-01 | ANG ROBERT | Director / Officer | F-InKind | D | Common Stock | 12,657 | 5.51 | 69.7K | 700,665 | — | ↗ |
| 2023-02-06 | Jorgensen Nathan D. | Officer | A-Award | A | Common Stock | 45,500 | 0.00 | — | 160,769 | — | ↗ |
| 2023-02-06 | Chakraborty Tirtha | Officer | A-Award | A | Employee Stock Option (right to buy) | 95,500 | 5.55 | 530.0K | 95,500 | — | ↗ |
| 2023-02-06 | Attar Eyal C. | Officer | A-Award | A | Common Stock | 54,500 | 0.00 | — | 54,500 | — | ↗ |
| 2023-02-06 | ANG ROBERT | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 257,500 | 5.55 | 1.43M | 257,500 | — | ↗ |
| 2022-12-09 | RA CAPITAL MANAGEMENT, L.P. | Director | A-Award | A | Common Stock | 11,627,907 | 4.30 | 50.00M | 20,923,554 | — | ↗ |
| 2022-10-11 | Attar Eyal C. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-09-01 | Jorgensen Nathan D. | Officer | A-Award | A | Employee Stock Option (right to buy) | 86,000 | 0.00 | — | 86,000 | — | ↗ |
| 2022-09-01 | Chakraborty Tirtha | Officer | A-Award | A | Employee Stock Option (right to buy) | 76,000 | 0.00 | — | 76,000 | — | ↗ |
| 2022-06-14 | Shah Rajeev M. | Director | A-Award | A | Stock Option (Right to Buy) | 16,911 | 0.00 | — | 16,911 | — | ↗ |
| 2022-06-14 | Resnick Joshua | Director | A-Award | A | Stock Option (right to buy) | 16,911 | 4.26 | 72.0K | 16,911 | — | ↗ |
| 2022-06-14 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 16,911 | 4.26 | 72.0K | 16,911 | — | ↗ |
| 2022-06-14 | Patterson Matthew R | Director | A-Award | A | Stock Option (right to buy) | 16,911 | 4.26 | 72.0K | 16,911 | — | ↗ |
| 2022-06-14 | PARMAR KUSH | Director | A-Award | A | Stock Option (right to buy) | 16,911 | 0.00 | — | 16,911 | — | ↗ |
| 2022-06-14 | Lundberg Sven Ante | Director | A-Award | A | Stock Option (right to buy) | 16,911 | 4.26 | 72.0K | 16,911 | — | ↗ |
| 2022-06-14 | Lubner David Charles | Director | A-Award | A | Stock Option (right to buy) | 16,911 | 4.26 | 72.0K | 16,911 | — | ↗ |
| 2022-06-14 | Beckman Daniella | Director | A-Award | A | Stock Option (right to buy) | 16,911 | 0.00 | — | 16,911 | — | ↗ |
| 2022-02-01 | Slapak Christopher | Officer | A-Award | A | Employee Stock Option (right to buy) | 116,000 | 8.63 | 1.00M | 116,000 | — | ↗ |
| 2022-02-01 | Jorgensen Nathan D. | Officer | A-Award | A | Employee Stock Option (right to buy) | 135,000 | 8.63 | 1.17M | 135,000 | — | ↗ |
| 2022-02-01 | Chakraborty Tirtha | Officer | A-Award | A | Employee Stock Option (right to buy) | 101,000 | 8.63 | 871.6K | 101,000 | — | ↗ |
| 2022-02-01 | ANG ROBERT | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 376,000 | 8.63 | 3.24M | 376,000 | — | ↗ |
| 2021-11-16 | PARMAR KUSH | Director / 10% Owner | S-Sale | D | Common Stock | 238,870 | 15.30 | 3.65M | 4,595,089 | — | ↗ |
| 2021-11-16 | 5AM Ventures VI, L.P. | 10% Owner | S-Sale | D | Common Stock | 91,836 | 15.30 | 1.41M | 1,766,634 | — | ↗ |
| 2021-08-17 | Chakraborty Tirtha | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 17,446 | 1.36 | 23.7K | 28,800 | — | ↗ |
| 2021-04-01 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | J-Other | A | Common Stock | 242,656 | 43.10 | 10.46M | 8,539,921 | — | ↗ |
| 2021-02-09 | RA CAPITAL MANAGEMENT, L.P. | Director / 10% Owner | C-Conversion | A | Common Stock | 280,330 | 0.00 | — | 280,330 | — | ↗ |
| 2021-02-09 | PARMAR KUSH | Director / 10% Owner | P-Purchase | A | Common Stock | 111,111 | 18.00 | 2.00M | 4,833,959 | — | ↗ |
| 2021-02-09 | Jorgensen Nathan D. | Officer | C-Conversion | A | Common Stock | 3,534 | 0.00 | — | 29,269 | — | ↗ |
| 2021-02-09 | Chakraborty Tirtha | Officer | C-Conversion | A | Common Stock | 3,534 | 0.00 | — | 3,534 | — | ↗ |
| 2021-02-09 | Alexandria Venture Investments, LLC | 10% Owner | C-Conversion | D | Series B convertible preferred stock | 3,846,152 | 0.00 | — | 0 | — | ↗ |
| 2021-02-09 | 5AM Ventures VI, L.P. | 10% Owner | C-Conversion | D | Series B Preferred Stock | 19,230,768 | 0.00 | — | 0 | — | ↗ |
| 2021-02-05 | Resnick Joshua | Director | A-Award | A | Stock Option (right to buy) | 16,900 | 18.00 | 304.2K | 16,900 | — | ↗ |
| 2021-02-05 | Patterson Matthew R | Director | A-Award | A | Stock Option (right to buy) | 16,900 | 18.00 | 304.2K | 16,900 | — | ↗ |
Executive team
Top executives
Shares Outstanding
6.85M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Jean-Paul Kress President, Chief Executive Officer and Chairman | 344.6K | 400.0K | — | 64.01M | 251.4K | 18.1K | 65.03M | 98.44% | ↗ |
| 2 | 2025 | Sandesh Mahatme Chief Financial Officer | 217.8K | 274.0K | 35.26M | 3.54M | 103.0K | 9.0K | 39.41M | 98.47% | ↗ |
| 3 | 2025 | Qing Zuraw Former Chief Development Officer | 243.4K | 100.0K | 2.23M | 8.57M | — | 692.7K | 11.84M | 91.25% | ↗ |
| 4 | 2025 | Robert Ang Former President and Chief Executive Officer | 515.0K | — | 184.3K | 1.18M | — | 1.49M | 3.36M | 40.46% | ↗ |
| 5 | 2024 | Robert Ang Former President and Chief Executive Officer | 620.9K | — | 361.5K | 864.8K | 341.5K | 31.6K | 2.22M | 55.23% | ↗ |
| 6 | 2024 | Robert Ang, M.B.B.S. Former President and Chief Executive Officer | 620.9K | — | 361.5K | 864.8K | 341.5K | 31.6K | 2.22M | 55.23% | ↗ |
| 7 | 2024 | Robert Ang, M.B.B.S. President and Chief Executive Officer | 620.9K | — | 361.5K | 864.8K | 341.5K | 31.6K | 2.22M | 55.23% | ↗ |
| 8 | 2024 | Eyal Attar, M.D. Chief Medical Officer | 487.1K | — | 150.6K | 230.0K | 195.3K | 12.8K | 1.08M | 35.38% | ↗ |
| 9 | 2024 | Eyal Attar, M.D. Former Chief Medical Officer | 487.1K | — | 150.6K | 230.0K | 195.3K | 12.8K | 1.08M | 35.38% | ↗ |
| 10 | 2024 | Tirtha Chakraborty, Ph.D. Chief Scientific Officer and Head of Technical Operations | 477.2K | — | 129.5K | 197.8K | 190.4K | 8.9K | 1.00M | 32.61% | ↗ |
| 11 | 2024 | Tirtha Chakraborty, Ph.D. Former Chief Scientific Officer and Head of Technical Operations | 477.2K | — | 129.5K | 197.8K | 190.4K | 8.9K | 1.00M | 32.61% | ↗ |
| 12 | 2023 | Robert Ang, M.B.B.S. President and Chief Executive Officer | 605.8K | — | 714.6K | 1.03M | 316.5K | 21.6K | 2.69M | 64.92% | ↗ |
| 13 | 2023 | Robert Ang, M.B.B.S. Former President and Chief Executive Officer | 605.8K | — | 714.6K | 1.03M | 316.5K | 21.6K | 2.69M | 64.92% | ↗ |
| 14 | 2023 | Eyal Attar, M.D. Former Chief Medical Officer | 474.0K | — | 302.5K | 437.1K | 180.3K | 6.3K | 1.40M | 52.82% | ↗ |
| 15 | 2023 | Eyal Attar, M.D. Chief Medical Officer | 474.0K | — | 302.5K | 437.1K | 180.3K | 6.3K | 1.40M | 52.82% | ↗ |
| 16 | 2023 | Eyal Attar, M.D. Chief Medical Officer | 474.0K | — | 302.5K | 437.1K | 180.3K | 6.3K | 1.40M | 52.82% | ↗ |
| 17 | 2023 | Tirtha Chakraborty, Ph.D. Chief Scientific Officer and Head of Technical Operations | 465.5K | — | 265.0K | 383.0K | 179.2K | 17.3K | 1.31M | 49.47% | ↗ |
| 18 | 2023 | Tirtha Chakraborty, Ph.D. Chief Scientific Officer | 465.5K | — | 265.0K | 383.0K | 179.2K | 17.3K | 1.31M | 49.47% | ↗ |
| 19 | 2023 | Tirtha Chakraborty, Ph.D. Former Chief Scientific Officer and Head of Technical Operations | 465.5K | — | 265.0K | 383.0K | 179.2K | 17.3K | 1.31M | 49.47% | ↗ |
| 20 | 2022 | Robert Ang, M.B.B.S. President and Chief Executive Officer | 570.0K | — | 857.3K | 2.79M | 285.0K | 20.5K | 4.52M | 80.64% | ↗ |
| 21 | 2022 | Nathan Jorgensen, Ph.D., M.B.A. Chief Financial Officer | 418.0K | — | 456.7K | 1.10M | 170.1K | 20.4K | 2.17M | 71.92% | ↗ |
| 22 | 2022 | Tirtha Chakraborty, Ph.D. Chief Scientific Officer | 430.0K | — | 403.6K | 866.5K | 172.6K | 20.4K | 1.89M | 67.09% | ↗ |
| 23 | 2021 | Robert Ang, M.B.B.S. President and Chief Executive Officer | 507.8K | — | — | 919.1K | 218.7K | 18.0K | 1.66M | 55.25% | ↗ |
| 24 | 2021 | Christopher Slapak, M.D. Chief Medical Officer | 428.0K | — | — | — | 150.6K | 12.0K | 590.6K | 0.00% | ↗ |
| 25 | 2021 | Tirtha Chakraborty, Ph.D. Chief Scientific Officer | 384.0K | — | — | — | 138.7K | 17.9K | 540.6K | 0.00% | ↗ |
| 26 | 2021 | Nathan Jorgensen, Ph.D., M.B.A. Chief Financial Officer | 382.9K | — | — | — | 138.6K | 17.9K | 539.4K | 0.00% | ↗ |
| 27 | 2020 | Robert Ang, M.B.B.S. President and Chief Executive Officer | 424.2K | — | — | 1.62M | 211.2K | 500.0K | 2.75M | 58.78% | ↗ |
| 28 | 2020 | Christopher Slapak, M.D. Chief Medical Officer | 176.8K | — | — | 627.4K | 136.8K | 283.3K | 1.22M | 51.24% | ↗ |
| 29 | 2020 | Tirtha Chakraborty, Ph.D. Chief Scientific Officer | 298.4K | 47.6K | — | 718.0K | 111.8K | 2.1K | 1.18M | 60.96% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Robert Ang MBBS | Strategic Advisor | 2M | — |
| Jean-Paul Kress | Chairman, President & CEO | 1M | — |
| Jeremy Sokolove | Chief Medical Officer | 695.2K | — |
| Sandesh Mahatme | Chief Business Officer & Chief Financial Officer | 603.8K | male |
| Qing Zuraw | Executive Officer | — | — |
| Adi Osovsky | General Counsel | — | female |
| Siddhartha Mukherjee DPHIL | Scientific Founder & Chairman of Scientific Advisory Board | — | — |
| Carol Lincoln | Head of Human Resources | — | female |
| Dallan Murray | Chief Commercial Officer | — | male |
| Navid Z. Khan | Chief Medical Affairs Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VOR
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
